Hyperuricemic patients with CKD
Conditions
Interventions
1)Febuxostat group CKD patients with hyperuricemia (Uric acid more than 6mg/dl) are scheduled to treat with 10 mg/day of febuxostat in the beginnings. The doses of febxostat are allowed to increase u
Sponsors
Yokohama City University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)adult(older than 19 years-old) 2)regardless of gender 3)Uric acid equal and more than 8mg/dl and the eGFR of less than 60ml/min/1.73m2 4)The general condition of the participants need to be stable. The participants should be treated according to the CKD practice guideline except uric acid treatment 5) Written informed consent should be obtained by all participants.
Exclusion criteria
Exclusion criteria: 1.The patients who are contraindicated to use febuxostat or allopurinol. 1)Patients who have liver injury(The ALT more than 200 IU/L) 2) Woman who is pregnat. 3) Patients who have allergy to febuxostat or allopurinol. 2. Patients who are judged as inadequate to participate the study by the their doctors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Serum Uric acid 2) Serum Cr, eGFR 3) Derum systatin C | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Urinary protein/Cr ratio 2) Urinary tubular markers/Cr ratio 3) Urinary uric acid excretion ratio | — |
Countries
Japan
Contacts
Public ContactNobuhito Hirawa
Yokohama City University Medical Center Department of hemodialysis and apheresis
Outcome results
None listed